What are the recommended first‑, second‑, and third‑line antihypertensive medications for an adult with uncomplicated primary hypertension, explained in simple terms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

First-, Second-, and Third-Line Antihypertensive Medications for Uncomplicated Primary Hypertension

First-Line Medications

For most adults with uncomplicated primary hypertension, start with a thiazide-like diuretic (chlorthalidone 12.5–25 mg daily), an ACE inhibitor, an ARB, or a long-acting calcium channel blocker. 1, 2

Specific First-Line Drug Names and Doses

Thiazide/Thiazide-Like Diuretics (Preferred):

  • Chlorthalidone 12.5–25 mg once daily – strongest cardiovascular outcome evidence, superior for preventing heart failure and stroke 1, 2, 3
  • Hydrochlorothiazide 25–50 mg once daily (less preferred than chlorthalidone) 1, 3
  • Indapamide 1.25–2.5 mg once daily 1, 4

ACE Inhibitors:

  • Lisinopril 10–40 mg once daily 1, 3
  • Enalapril 5–40 mg once or twice daily 1, 5
  • Ramipril 2.5–20 mg once daily 1, 3

Angiotensin Receptor Blockers (ARBs):

  • Losartan 50–100 mg once daily 1, 5
  • Valsartan 80–320 mg once daily 1
  • Olmesartan 20–40 mg once daily 1

Long-Acting Calcium Channel Blockers:

  • Amlodipine 5–10 mg once daily 1, 2, 4
  • Extended-release nifedipine 30–90 mg once daily 1, 4

When to Use Monotherapy vs. Combination

Stage 1 hypertension (130–139/80–89 mmHg): Start with a single agent, titrate upward, then add a second drug from a different class if target not reached after 4 weeks 1, 2, 5

Stage 2 hypertension (≥140/90 mmHg or >20/10 mmHg above goal): Begin immediately with two-drug combination therapy, preferably as a single-pill formulation 1, 2, 5

Population-Specific First-Line Choices

Black patients without heart failure or CKD: Thiazide diuretic (chlorthalidone) or calcium channel blocker (amlodipine) – ACE inhibitors and ARBs are 30–36% less effective for stroke prevention in this population 1, 2, 5

Patients with diabetes: ACE inhibitor or ARB as initial therapy to protect kidney function 1, 4, 5

Patients with chronic kidney disease (stage 3+ or albuminuria ≥300 mg/day): ACE inhibitor or ARB 1, 4, 5

Second-Line Medications (Add-On Therapy)

When blood pressure remains ≥130/80 mmHg after 4 weeks on a single first-line agent at optimal dose, add a second drug from a different first-line class rather than maximizing the dose of the first drug. 1, 2, 5

Preferred Two-Drug Combinations

Most effective second-line combinations:

  • Thiazide diuretic + ACE inhibitor or ARB 1, 5
  • Calcium channel blocker + ACE inhibitor or ARB 1, 5

For Black patients:

  • Thiazide diuretic + calcium channel blocker 1, 4

Beta-Blockers (Conditional Second-Line)

Beta-blockers should NOT be used as first-line therapy in uncomplicated hypertension, especially in patients >60 years, because they are approximately 36% less effective than calcium channel blockers and 30% less effective than thiazides for stroke prevention. 1, 2, 4, 5

Use beta-blockers as second-line only when there is a compelling indication:

  • Post-myocardial infarction (continue ≥3 years) 1, 5
  • Active angina 1, 5
  • Heart failure with reduced ejection fraction 1, 5

Specific beta-blocker names and doses:

  • Metoprolol succinate 50–200 mg once daily 1
  • Carvedilol 12.5–50 mg twice daily 1
  • Bisoprolol 2.5–10 mg once daily 1

Third-Line Medications (Triple Therapy)

If blood pressure remains ≥130/80 mmHg on two first-line agents at optimal doses, escalate to triple therapy: ACE inhibitor or ARB + calcium channel blocker + thiazide-like diuretic, preferably as a single-pill combination. 1, 4, 5

Fourth-Line for Resistant Hypertension

When blood pressure remains uncontrolled on three-drug therapy (including a diuretic), add:

Mineralocorticoid Receptor Antagonist (Preferred Fourth Agent):

  • Spironolactone 25–50 mg once daily – most effective fourth-line agent for resistant hypertension 1, 4, 5
  • Eplerenone 50–100 mg once or twice daily (less gynecomastia than spironolactone) 1

Alternative Fourth-Line Agents (if spironolactone contraindicated):

  • Doxazosin 1–16 mg once daily (alpha-blocker) 1
  • Hydralazine 100–200 mg twice daily (direct vasodilator) 1
  • Clonidine 0.1–0.8 mg twice daily (central alpha-agonist) 1

Critical Monitoring for Spironolactone

Before starting spironolactone, verify serum potassium <5.0 mmol/L and eGFR >30 mL/min/1.73 m². 1, 4

Recheck potassium and creatinine within 1–2 weeks of initiation, after each dose increase, and every 3–6 months thereafter. 1, 4, 5

Medications to Avoid as First-Line

Alpha-blockers (doxazosin): Not first-line – 80% higher heart failure rate compared to chlorthalidone in ALLHAT trial 1, 2, 5

Beta-blockers: Not first-line in uncomplicated hypertension – inferior stroke prevention 1, 2, 4, 5

Dual RAS blockade: Never combine ACE inhibitor + ARB (or add aliskiren) – increases hyperkalemia and acute kidney injury without cardiovascular benefit 1, 4, 5

Blood Pressure Targets

Target <130/80 mmHg for all adults with hypertension, including those with diabetes, chronic kidney disease, or cardiovascular disease. 1, 2, 5

In high-risk patients, avoid lowering diastolic pressure below 60–70 mmHg – excessive reduction may increase adverse cardiovascular events. 1, 5

Follow-Up Schedule

Monthly visits after initiating or adjusting therapy until target blood pressure is achieved. 1, 2, 5

Every 3–5 months once blood pressure is controlled. 1, 2, 5

Space dose adjustments at least 4 weeks apart to allow full blood pressure response. 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

First-Line Medication for Male Hypertension

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Hypertension Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Hypertension Diagnosis, Treatment Targets, and Management in Adults

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the treatment approach for an adult patient with a history of hypertension or at risk for cardiovascular disease using Prichard's regimen?
What is the first-line treatment for an adult patient with primary hypertension?
What is the first‑line antihypertensive medication for an elderly (geriatric) patient with hypertension?
What is the management for elevated diastolic blood pressure?
What are the initial antihypertensive (blood pressure-lowering) medication dosages for managing hypertension?
What is the recommended stepwise pharmacologic treatment for uncomplicated primary hypertension in adults, including first‑line, second‑line, and third‑line agents, safe drug combinations, kidney‑protective options for patients with diabetes, chronic kidney disease, or proteinuria, and identification of each medication as a beta‑blocker, calcium‑channel blocker, or ACE inhibitor/ARB?
What does recovery after an anterior cervical discectomy and fusion (ACDF) at the C5‑C6 level involve?
What are the common presenting symptoms of giant cell arteritis in patients over 50 years old, especially women?
How does recovery after a multi‑level anterior cervical discectomy and fusion (ACDF) differ from recovery after a single‑level ACDF?
What is the recommended approach to managing constipation in a patient on hemodialysis, including dietary measures, safe laxatives, and medication adjustments?
Can a patient be started on Ozempic (semaglutide) 0.5 mg subcutaneously without first using the 0.25 mg starter dose?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.